The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019. However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose, and treat the diseases Our team […]Read More
Shots: The approval is based on P-III OLYMPUS trial results assessing Jelmyto in 74 adults with LG UTUC to evaluate its safety, tolerability and tumor ablative effect across the US and Israel The study resulted in CR 58%, Kaplan-Meier analysis estimated 12-month durability at 84%, median duration of response has not been reached, no treatment-related […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
